<table id="ID71" width="101%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4 Efficacy Outcomes within Demographic Subgroups</caption>
<col span="1" width="11%"></col>
<col span="1" width="7%"></col>
<col span="1" width="15%"></col>
<col span="1" width="11%"></col>
<col span="1" width="14%"></col>
<col span="1" width="18%"></col>
<col span="1" width="11%"></col>
<col span="1" width="14%"></col>
<tbody>
<tr>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>Primary Composite Endpoint<br/>
</td>
<td>ESRD<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>No. of<br/>Patients<br/>
</td>
<td>Losartan Potassium<br/>Tablets Event Rate %<br/>
</td>
<td>Placebo Event<br/>Rate %<br/>
</td>
<td>Hazard Ratio<br/>(95% CI)<br/>
</td>
<td>Losartan Potassium Tablets<br/>Event Rate %<br/>
</td>
<td>Placebo Event<br/>Rate %<br/>
</td>
<td>Hazard Ratio<br/>(95% CI)<br/>
</td>
</tr>
<tr>
<td>Overall Results<br/>
</td>
<td>1513<br/>
</td>
<td>43.5<br/>
</td>
<td>47.1<br/>
</td>
<td>0.839 (0.721, 0.977)<br/>
</td>
<td>19.6<br/>
</td>
<td>25.5<br/>
</td>
<td>0.714 (0.576, 0.885)<br/>
</td>
</tr>
<tr>
<td>Age<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>   &lt;65  years<br/>
</td>
<td>1005<br/>
</td>
<td>44.1<br/>
</td>
<td>49.0<br/>
</td>
<td>0.784 (0.653, 0.941)<br/>
</td>
<td>21.1<br/>
</td>
<td>28.5<br/>
</td>
<td>0.670 (0.521, 0.863)<br/>
</td>
</tr>
<tr>
<td>   ≥65 years<br/>
</td>
<td>508<br/>
</td>
<td>42.3<br/>
</td>
<td>43.5<br/>
</td>
<td>0.978 (0.749, 1.277)<br/>
</td>
<td>16.5<br/>
</td>
<td>19.6<br/>
</td>
<td>0.847 (0.560, 1.281)<br/>
</td>
</tr>
<tr>
<td>Gender<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>   Female<br/>
</td>
<td>557<br/>
</td>
<td>47.8<br/>
</td>
<td>54.1<br/>
</td>
<td>0.762 (0.603, 0.962)<br/>
</td>
<td>22.8<br/>
</td>
<td>32.8<br/>
</td>
<td>0.601 (0.436, 0.828)<br/>
</td>
</tr>
<tr>
<td>   Male<br/>
</td>
<td>956<br/>
</td>
<td>40.9<br/>
</td>
<td>43.3<br/>
</td>
<td>0.892 (0.733, 1.085)<br/>
</td>
<td>17.5<br/>
</td>
<td>21.5<br/>
</td>
<td>0.809 (0.605, 1.081)<br/>
</td>
</tr>
<tr>
<td>Race<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>   Asian<br/>
</td>
<td>252<br/>
</td>
<td>41.9<br/>
</td>
<td>54.8<br/>
</td>
<td>0.655 (0.453, 0.947)<br/>
</td>
<td>18.8<br/>
</td>
<td>27.4<br/>
</td>
<td>0.625 (0.367, 1.066)<br/>
</td>
</tr>
<tr>
<td>   Black<br/>
</td>
<td>230<br/>
</td>
<td>40.0<br/>
</td>
<td>39.0<br/>
</td>
<td>0.983 (0.647, 1.495)<br/>
</td>
<td>17.6<br/>
</td>
<td>21.0<br/>
</td>
<td>0.831 (0.456, 1.516)<br/>
</td>
</tr>
<tr>
<td>   Hispanic<br/>
</td>
<td>277<br/>
</td>
<td>55.0<br/>
</td>
<td>54.0<br/>
</td>
<td>1.003 (0.728, 1.380)<br/>
</td>
<td>30.0<br/>
</td>
<td>28.5<br/>
</td>
<td>1.024 (0.661, 1.586)<br/>
</td>
</tr>
<tr>
<td>   White<br/>
</td>
<td>735<br/>
</td>
<td>40.5<br/>
</td>
<td>43.2<br/>
</td>
<td>0.809 (0.645, 1.013)<br/>
</td>
<td>16.2<br/>
</td>
<td>23.9<br/>
</td>
<td>0.596 (0.427, 0.831)<br/>
</td>
</tr>
</tbody>
</table>